

SWIXX NAMED ONE OF SWITZERLAND'S BEST MANAGED COMPANIES FOR SECOND CONSECUTIVE YEAR

Baar, Switzerland, June 26th, 2026 – Swixx Biopharma AG today announced that it has once again been named one of Switzerland's Best Managed Companies by Deloitte. This marks the second consecutive year that Swixx has received this prestigious recognition, confirming the company's continued strength in strategy, operational excellence, governance, financial performance and people-focused culture.


The Best Managed Companies programme, run by Deloitte, is an internationally recognized programme that evaluates businesses based on their leadership across strategy, culture and commitment, capabilities and innovation, governance and financial performance. The Switzerland awards are based on more than 30 years of observed practice from Deloitte's global awards programme, with applicants assessed by an independent panel of judges.

Swixx first received the award in 2025, when it was recognized for its strong business performance, sustained growth and ability to translate strategy into meaningful impact across markets and stakeholders. Being recognized again in 2026 underlines Swixx's ability to sustain momentum while strengthening the foundations for long-term success.

Over the past year, Swixx has reinforced this momentum through several important milestones, including the successful integration of Lundbeck across more than 30 countries, continued company's growth and expansion, progress in ESG and the strategic investment by SK Capital, which brings additional resources, healthcare expertise and capabilities to support the company's next phase of sustainable growth and global expansion.

The recognition also reflects Swixx's continued evolution and excellence as a multi-regional commercialization platform. In an increasingly complex healthcare environment, pharmaceutical and biotech companies are placing greater emphasis on strategic partnerships, coordinated launch execution and reliable access in non-core geographies. Swixx's affiliate-equivalent model, pan-regional perspective and growing digital and omnichannel capabilities are enabling the company to support Partners with greater predictability, agility and confidence across its markets.

 **Barbara Košir, NED and ESG Ambassador of Swixx Biopharma**, said: "Being recognized as one of Switzerland's Best Managed Companies for the second year in a row is a strong endorsement of the way Swixx continues to grow: with strategic discipline, operational agility and a clear focus on partners, patients and our people. Over the past year, our teams successfully integrated a multiregional partnership with flawless business continuity, advanced our ESG and governance agenda and prepared Swixx for its next phase of expansion. This award belongs to our teams across all markets, whose commitment and execution make our growth possible."

 **Andreas Bodenmann, Best Managed Companies Programme Lead at Deloitte Switzerland**, emphasized: "The companies honored with this year's Best Managed Companies Award are at the forefront of their respective industries. They have achieved something extraordinary. In a highly volatile and challenging environment, the management teams have impressively demonstrated that they lead and develop their companies in an exemplary manner, thereby enhancing their competitiveness. The companies can rightly be very proud of this."



About Swixx Biopharma

Swixx Biopharma is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Biopharma operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With a presence in 45+ countries and sales expected to reach €1.3 billion in 2026, Swixx is one of the fastest-growing independent biopharma commercialization platforms. Gathering outstanding rare disease, oncology-hematology, CNS, specialty and vaccines talent under one roof, Swixx Biopharma entered 2026 with more than 1,700 employees on board. For more information about Swixx, please visit: www.swixxbiopharma.com.



Swixx Group media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director
vedrana.sokac@swixxbiopharma.com, Tel: +385 1 425 6086

